Jeffrey Hopland, MD
Family Medicine · Johnson City, TNNPI 1497755490
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 543 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 543 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$937
- AstraZeneca$913
- Amgen$651
- Boehringer Ingelheim$619
- Novo Nordisk$528
- plus $4K from 39 others
Across 84 payments — averaging $9444.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seqirus USA Inc$205K
- Amgen$176K
- Cue Health Inc.$172K
- AstraZeneca$115K
- Genentech, Inc.$94K
- Modernatx, Inc.$32K
What the payments were for
- Food & beverage$8,481100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$125
- Inpefa$122
- BREZTRI AEROSPHERE$118
- EVENITY$111
- XIFAXAN$100
How this compares
$8,496 in reported general payments places this provider in the 90th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 155 | $221,484 |
| JardianceEmpagliflozin | 135 | $199,662 |
| EliquisApixaban | 144 | $125,237 |
| OzempicSemaglutide | 100 | $112,076 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $54,637 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $52,245 |
| FarxigaDapagliflozin Propanediol | 43 | $46,549 |
| VascepaIcosapent Ethyl | 35 | $32,452 |
| VraylarCariprazine Hcl | 21 | $31,342 |
| TrulicityDulaglutide | 18 | $29,295 |
| EntrestoSacubitril/Valsartan | 24 | $27,695 |
| JanuviaSitagliptin Phosphate | 15 | $24,741 |
| LinzessLinaclotide | 22 | $22,426 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 24 | $22,215 |
| XareltoRivaroxaban | 21 | $19,737 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $419 | $250,779173 claims |
| Boehringer IngelheimJardiance, Glyxambi, Spiriva Respimat | $619 | $225,223162 claims |
| PfizerEliquis | $316 | $125,237144 claims |
| Novo NordiskOzempic | $528 | $112,076100 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $913 | $68,83677 claims |
| GSKTrelegy Ellipta | $937 | $54,63760 claims |
| AbbVieVraylar, Linzess | $1,124 | $53,76743 claims |
| MerckJanuvia, Belsomra | $296 | $33,40935 claims |
| NovartisEntresto | $297 | $27,69524 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $157 | $22,21524 claims |
| Johnson & JohnsonXarelto | $34 | $19,73721 claims |
| Astellas Pharma US IncMyrbetriq | $29 | $17,14727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Johnson City
- Leigh JohnsonJohnson City$30K
- Kevin DennisFranklin$354K
- Charolette JacksonBartlett$162K
- Keren HolmesNashville$58K
- Kabir Harricharan SinghNewport$49K
- Khaisha GistAntioch$49K
- Jerry PunchKnoxville$45K
- Christopher HollowayAntioch$41K
- Curtis JantziKingsport$39K
- Ellen ClelandChattanooga$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.